Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

$75.47 -0.55 (-0.73%)

As of 03:20 PM Eastern

Compare

Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
1

Hold
2

Buy
18

Based on 21 Wall Street analysts who have issued ratings for Ionis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 1 has given a sell rating, 2 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for IONS.

Consensus Price Target

$99.35
31.65% Upside

According to the 21 analysts' twelve-month price targets for Ionis Pharmaceuticals, the average price target is $99.35. The highest price target for IONS is $130.00, while the lowest price target for IONS is $65.00. The average price target represents a forecasted upside of 31.65% from the current price of $75.47.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IONS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ionis Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IONS Analyst Ratings Over Time

Type	Current Forecast 5/8/25 to 5/8/26	1 Month Ago 4/8/25 to 4/8/26	3 Months Ago 2/7/25 to 2/7/26	1 Year Ago 5/8/24 to 5/8/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	12 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$99.35	$92.84	$86.95	$56.67
Forecasted Upside	31.65% Upside	23.82% Upside	0.52% Upside	73.03% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IONS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IONS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ionis Pharmaceuticals Stock vs. The Competition

Type	Ionis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	30.69% Upside	840.78% Upside	14.95% Upside
News Sentiment Rating	Positive News See Recent IONS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/30/2026	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform	$111.00	+47.28%
4/30/2026	HC Wainwright 3 of 5 stars	Mitchell S. Not Rated	Boost Target	Buy	$120.00 ➝ $125.00	+67.05%
4/30/2026	Barclays 3 of 5 stars	Eliana Merle Not Rated	Boost Target	Overweight	$106.00 ➝ $115.00	+53.68%
4/30/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$95.00 ➝ $100.00	+33.77%
4/23/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Werber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$110.00 ➝ $108.00	+44.76%
4/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
4/21/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ulz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$95.00 ➝ $130.00	+73.63%
4/20/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$110.00	+46.92%
4/10/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tiago Fauth Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$104.00	+38.15%
4/9/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Gerberry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $111.00	+45.83%
Get the Latest News and Ratings for IONS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
3/25/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$103.00 ➝ $105.00	+43.52%
3/3/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$102.00 ➝ $104.00	+31.58%
2/27/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allison Bratzel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$87.00 ➝ $100.00	+23.05%
2/26/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$73.00 ➝ $77.00	-5.60%
1/5/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yanan Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$82.00 ➝ $100.00	+25.52%
10/8/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$49.00 ➝ $80.00	+16.04%
9/26/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$45.00 ➝ $65.00	+3.22%
9/23/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$90.00 ➝ $92.00	+49.93%
9/3/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lebowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$69.00 ➝ $84.00	+39.66%
9/3/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$40.00 ➝ $70.00	+21.76%
9/2/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$83.00 ➝ $96.00	+67.15%
3/31/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$39.00	+25.20%
12/20/2024	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
6/14/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$44.00	+7.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:21 PM ET.

IONS Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Ionis Pharmaceuticals is $99.35, with a high forecast of $130.00 and a low forecast of $65.00.

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 2 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IONS shares.

According to analysts, Ionis Pharmaceuticals's stock has a predicted upside of 31.65% based on their 12-month stock forecasts.

Over the previous 90 days, Ionis Pharmaceuticals's stock had 2 upgrades by analysts.

Ionis Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, HC Wainwright, Leerink Partners, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, and Weiss Ratings in the past 90 days.

Analysts like Ionis Pharmaceuticals more than other "medical" companies. The consensus rating for Ionis Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IONS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Ionis Pharmaceuticals Recommendations

This page (NASDAQ:IONS) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

IONS Analyst Ratings Over Time

IONS Analyst Recommendations By Month

IONS Price Targets by Month

Ionis Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

IONS Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Ionis Pharmaceuticals Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

IONS Analyst Ratings Over Time

IONS Analyst Recommendations By Month

IONS Price Targets by Month

Ionis Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

IONS Forecast - Frequently Asked Questions

What is Ionis Pharmaceuticals' forecast for 2026?

Should I buy or sell Ionis Pharmaceuticals stock right now?

Does Ionis Pharmaceuticals's stock price have much upside?

Has Ionis Pharmaceuticals been upgraded by Wall Street analysts recently?

What analysts cover Ionis Pharmaceuticals?

Do Wall Street analysts like Ionis Pharmaceuticals more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Ionis Pharmaceuticals Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools